Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial
Sadahisa Ogasawara, Keisuke Koroki, Hirokazu Makishima, Masaru Wakatsuki, Asahi Takahashi, Sae Yumita, Miyuki Nakagawa, Takamasa Ishino, Keita Ogawa, Kisako Fujiwara, Terunao Iwanaga, Takafumi Sakuma, Naoto Fujita, Ryuta Kojima, Hiroaki Kanzaki, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Tomoko Saito, Takayuki Kondo, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Tetsuhiro Chiba, Yoshihito Ozawa, Yohei Kawasaki, Tomoya Kurokawa, Hideki Hanaoka, Hiroshi Tsuji, Naoya Kato
BMJ Open Apr 2022, 12 (4) e059779; DOI: 10.1136/bmjopen-2021-059779